Publications (2008-2009)
1. Kraiczy, P., Seling, A., Brissette, C. A., Rossmann, E., Hunfeld, K.-P., Bykowski, T., Burns,
L. H., Troese, M. J., Cooley, A.E., Miller, J. C., Brade, V., Wallich, R., Casjens, S., and B. Stevenson. Antibodies against Borrelia burgdorferi complement regulator-acquiring surface protein 2 (CspZ) as a serological marker of human Lyme disease. Clin. Vaccine Immunol., 2008, 15: 484-491. 2. Besier, S., J. Zander, B.C. Kahl, P. Kraiczy, V. Brade, T.A. Wichelhaus.The thymidine-
dependent small colony variant phenotype is associated with 2 hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother., 2008, 52: 2183-2189. 3. Bykowski, T., M. E. Woodman, A. E. Cooley, C. A. Brissette, R. Wallich, V. Brade, P.
Kraiczy, and B. Stevenson. Borrelia burgdorferi complement regulator-acquiring surface
proteins (BbCRASPs): Expression patterns during mammal-tick infection cycle. Int. J. Med.
Microbiol. 2008, 298 S1: 249-256.
4. Haupt, K., P. Kraiczy, R. Wallich, V. Brade, C. Skerka, and P. F. Zipfel. FHR-1, an
additional human plasma protein, binds to complement regulator-acquiring surface proteins of Borrelia burgdorferi. Int. J. Med. Microbiol., 2008, 298 S1: 287-291. 5. Hunfeld, K.P., Burg, S., Hanssen-Hübner, C., Karas, M., Brade, V., and P. Kraiczy. Changes
in the expression pattern of structural proteins after exposure of Borrelia burgdorferi to penicillin G and doxycycline. Int. J. Med. Microbiol., 2008, 298 S1: 325-332. 6. Siegel, C., P. Herzberger, C. Skerka, V. Brade, V. Fingerle, U. Schulte-Spechtel, B. Wilske, P. F. Zipfel, R. Wallich, and P. Kraiczy. Binding of complement regulatory protein factor H
enhance serum resistance of B. spielmanii sp. nov. Int. J. Med. Microbiol., 2008, 298 S1: 292-
7. Kraiczy, P., J. Schreiber, C. Skerka, K. Haupt, V. Brade, R. Wallich, P.F. Zipfel. Assessment
of the regions within complement regulator-acquiring surface protein (CRASP)-2 of Borrelia burgdorferi required for interaction with host immune regulators FHL-1 and factor H. Int. J. Med. Microbiol., 2008, 298 S1:268-271. 8. Rossmann, E., P. Kraiczy, P. Herzberger, C. Skerka, M. Kirschfink, M. M. Simon, P. F.
Zipfel, and R. Wallich. BhCRASP-1 of relapsing fever spirochetes Borrelia hermsii is a factor H- and plasminogen-binding protein. Int. J. Med. Microbiol., 2008, 298 S1: 272-283. 9. Rossmann, E., V. Kitiratschky, H. Hoffman, M. M. Simon, P. Kraiczy, and R. Wallich.
BbCRASP-1 of the Lyme disease spirochetes induce antibodies to non-denatured structural determinants in humans. Int. J. Med. Microbiol., 2008, 298 S1: 284-286. 10. Sadik, C.D., Hunfeld, K.-P., Bachmann, M., Kraiczy, P., Eberhardt, W., Brade, V.,
Pfeilschifter, J., H. Mühl. Systematic analysis highlights the key role of TLR2/NF-B/MAP kinase signaling for IL-8 induction by macrophage-like THP-1 cells under influence of Borrelia burgdorferi lysates. Int. J. Biochem. Cell Biol. 2008, 40: 2508-2521. 11. Siegel, C., Schreiber, J., Haupt, K., Skerka, C., Brade, V., Simon, M.M., Stevenson, B., Wallich, R., Zipfel, P.F., and P. Kraiczy. Deciphering the ligand-binding sites in the Borrelia
complement regulator-acquiring surface protein 2 (BbCRASP-2) required for
interactions with the human immune regulators factor H and factor H-like protein 1. J. Biol.
Chem., 2008, 283: 34855-34863.
12. Poggensee, G., Fingerle, V., Hunfeld, K.-P., Kraiczy, P., Krause, A., Matuschka, F.-R.,
Richter, D., Simon, M.M., Wallich, R., Hofman, H., Kohn, B., Lierz, M., Linde, A., Schneider, T., Strfaubinger, R., Stark, K., Süss, J., Talaska, T., und A. Jansen. Lyme-Borreliose: Forschungsbedarf und Forschungsansätze. Bundesgesundheitsblatt 2008, 50: 1329-1339. 13. Brissette, C.A., Haupt, K., Barthel, D., Cooley, A.E., Bowman, A., Skerka, C., Wallich, R., Zipfel, P.F., Kraiczy, P., and B. Stevenson. The Borrelia burgdorferi infection-associated
surface proteins ErpP, ErpA, and ErpC bind human plasminogen. Infect. Immun. 2009, 77:
14. Herzberger, P., C. Siegel, C. Skerka, V. Fingerle, U. Schulte-Spechtel, B. Wilske, V. Brade, P. F. Zipfel, R. Wallich, and P. Kraiczy. Identification and characterization of the factor H and
FHL-1 binding complement regulator-acquiring surface protein 1 of the Lyme disease
spirochete Borrelia spielmanii sp. nov. Int. J. Med. Microbiol., 2009, 299: 141-154.
15. Morgenstern, K., Baljer, G., Norris, D.E., Kraiczy, P., Hanssen-Hübner, C., and K.-P.
Hunfeld. In vitro susceptibility of Borrelia spielmanii against antimicrobial agents commonly used for the treatment of Lyme disease. Antimicrob. Agents Chemother., 2009, 53: 1281-1284. 16. Grosskinsky S., Schott, M., Brenner, C., Cutler, S.J., Kraiczy, P., Zipfel, P.F., Simon, M.M.,
and R. Wallich. Borrelia recurrentis employs a novel multifunctional surface protein with anti-complement, anti-opsonic and invasive potential to escape innate immunity. PLoS ONE. 2009, 4:e4858. 17. Kraiczy, P., Hanssen-Hübner, C., Kitiratschky, V., Brenner, C., Besier, S., Brade, V., Simon,
M. M., Skerka, C., Roversi, P., Lea, S. M., Stevenson, B., Wallich, R., and P. F. Zipfel. Mutational analyses of the BbCRASP-1 protein of Borrelia burgdorferi identifies residues relevant for the architecture and binding of the host complement regulators FHL-1 and factor H. Int. J. Med. Microbiol., 2009, 299: 255-268. 18. Hunfeld, K.-P., and P. Kraiczy. When is the best time to order a Western blot and how should
it be interpreted? Curr. Probl. Dermatol., 2009, 37: 167-177. 19. Kenedy, M. R., Vuppala, S. R., Siegel, C., Kraiczy, P., and D. R. Akins. CspA-mediated
binding of human factor H inhibits complement deposition and confers serum resistance in Borrelia burgdorferi. Infect. Immun., 2009, 77: 2773-2782.



Weekly Update Care December 27, 2007 In The Know… PBM and Plan Updates Generic Altace® Now Available Nationwide Updates Cobalt Laboratories launched Ramipril – the generic form of Altace – on 12/26. Altace is an ACE inhibitor used in the treatment of hypertension and has retail sales of • Effective 1/1/08, 4D will begin processing claims for AAA of Michig


The Influence of Music Therapy Over Delayed Nausea Vomiting As Chemotherapy Effect On School Age Who Suffer Cancer At RSUP Dr. Hasan Sadikin Bandung Music therapy is an effecive therapy to reduce delayed nausea vomiting as chemotherapy effect. The purpose of this research is to identify the effect of music therapy over delayed nausea vomiting on school age who suffers for cancer. This research d

Copyright © 2010 Medicament Inoculation Pdf